Now showing items 1-10 of 16
HPA axis activity in patients with panic disorder: review and synthesis of four studies
(Wiley Subscription Services, Inc., A Wiley Company, 2007)
Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis may play a role in panic disorder. HPA studies in patients with panic disorder, however, have produced inconsistent results. Seeking to understand the ...
Childhood adversity and vulnerability to mood and anxiety disorders
(John Wiley & Sons, Inc., 1997)
Based upon epidemiological surveys, adverse childhood events are proposed to be risk factors for adult depressive and anxiety disorders. However, the extent to which these events are seen in clinical patient populations ...
Acute onset and remission of obsessions and compulsions following medical illnesses and stress
(John Wiley & Sons, Inc., 2000)
Obsessive Compulsive Disorder (OCD) is generally chronic. Episodic OCD with complete remission has been rarely reported. Two cases of brief, episodic obsessions and compulsions that appeared for the first time following ...
Cardiac and neuroendocrine responses to exposure therapy in height phobics: Desynchrony within the `physiological response system'
(Elsevier, 1989)
Subjective, behavioral, cardiovascular and neuroendocrine responses were intensively monitored in two height phobics over a full course of exposure therapy and at follow-up. Both subjects showed rising cortisol responses ...
Discontinuation of Alprazolam after successful treatment of panic disorder: a naturalistic follow-up study
(Elsevier, 1993)
Low rates of benzodiazepine discontinuation have been seen in long-term outcome studies of alprazolam-treated panic disorder. Discontinuation studies reveal high rates of relapse when alprazolam is stopped. Available data ...
Pentagastrin infusions in patients with panic disorder II. Neuroendocrinology
(Elsevier, 1994-07-15)
Cholecystokinin (CCK) has well-documented anxiogenic effects in animals and normal people, and panicogenic effects in patients with panic disorder, but little is known about its neuroendocrine profile. We examined ...
Pentagastrin infusions in patients with panic disorder I. Symptoms and cardiovascular responses
(Elsevier, 1994-07-15)
Cholecystokinin (CCK) may mediate human anxiety and animal data suggest that cholecystokinin antagonists could provide an important advance in the treatment of anxiety disorders. The study of CCK receptor systems in ...
Group behavioral therapy of obsessive-compulsive disorder: Seven- vs. twelve-week outcomes
(John Wiley & Sons, Inc., 2001)
Previous research has demonstrated that individualized behavioral exposure and response prevention therapy is an effective treatment for Obsessive-Compulsive Disorder. In our prior preliminary report, 7-week group exposure ...
Alpha2-adrenoceptor status in obsessive-compulsive disorder
(Elsevier, 1990-05-15)
Ten patients with obsessive-compulsive disorder (OCD) and 13 normal control subjects received intravenous infusions of 2 x 10-6 g/kg of clonidine and normal saline on separate days. Responses to the drug relating to ...